Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
Aligos Therapeutics, Inc. (ALGS)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/03/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 08/01/2023 |
8-K
| Quarterly results |
| 07/25/2023 |
8-K
| Quarterly results |
| 07/21/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/21/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/21/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/21/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/21/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/04/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/04/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 04/28/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/28/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/28/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/17/2023 |
4
| McClure Matthew W. (Chief Medical Officer) has filed a Form 4 on Aligos Therapeutics, Inc.|
Txns:
| Granted 75,000 options to buy
@ $1.34, valued at
$100.5k
|
|
| 03/17/2023 |
4
| Symons Julian A. (See Remarks) has filed a Form 4 on Aligos Therapeutics, Inc.|
Txns:
| Granted 78,750 options to buy
@ $1.34, valued at
$105.5k
|
|
| 03/17/2023 |
4
| Calhoun Lesley Ann (See Remarks) has filed a Form 4 on Aligos Therapeutics, Inc.|
Txns:
| Granted 78,750 options to buy
@ $1.34, valued at
$105.5k
|
|
| 03/17/2023 |
4
| Quan Lucinda Y. (See Remarks) has filed a Form 4 on Aligos Therapeutics, Inc.|
Txns:
| Granted 78,750 options to buy
@ $1.34, valued at
$105.5k
|
|
| 03/17/2023 |
4
| Beigelman Leonid (President) has filed a Form 4 on Aligos Therapeutics, Inc.|
Txns:
| Granted 169,500 options to buy
@ $1.34, valued at
$227.1k
|
|
| 03/17/2023 |
4
| BLATT LAWRENCE (CEO) has filed a Form 4 on Aligos Therapeutics, Inc.|
Txns:
| Granted 242,500 options to buy
@ $1.34, valued at
$325k
|
|
| 03/09/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/09/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/09/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 02/14/2023 |
SC 13G/A
| TANG CAPITAL PARTNERS LP reports a 7.1% stake in Aligos Therapeutics, Inc. |
| 02/13/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/09/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/08/2023 |
SC 13G/A
| BLATT LAWRENCE reports a 6.5% stake in Aligos Therapeutics, Inc. |
| 12/27/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 11/02/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/02/2022 |
8-K
| Quarterly results |
| 08/04/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/04/2022 |
8-K
| Quarterly results |
| 07/11/2022 |
4
| McClure Matthew W. (Chief Medical Officer) has filed a Form 4 on Aligos Therapeutics, Inc.|
Txns:
| Granted 46,000 options to buy
@ $1.41, valued at
$64.9k
|
|
| 07/11/2022 |
4
| Quan Lucinda Y. (See Remarks) has filed a Form 4 on Aligos Therapeutics, Inc.|
Txns:
| Granted 52,500 options to buy
@ $1.41, valued at
$74k
|
|
| 07/11/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
|
|
|